On the afternoon of July 18, Hao Haiping, Dean of the School of Pharmacy, China Pharmaceutical University, and Deputy Director of the State Key Laboratory of "Active Components and Efficacy of Natural Medicines", led a group of 7 people to visit Wanbangde Pharmaceutical Group. The arrival of Professor Hao Haiping and his entourage was warmly welcomed by Lin Jianmin, Deputy Mayor of Wenling City, Tong Qingbo, Director of the Market Supervision Bureau, and Zhao Shouming, Chairman of the Board of Directors.

Accompanied by Chairman Zhao Shouming, Hao Haiping and his entourage visited the product exhibition hall and the ginkgo leaf dropping pill workshop successively, and held a symposium to learn more about the company's development.

At the symposium, Chairman Zhao Shouming gave a comprehensive introduction to the company's development history and future development plan, and gave a brief introduction to the sales of Wanbond Pharmaceuticals in the first half of this year: the sales performance of Wanbond Pharmaceuticals increased by 82% compared with the first half of last year, ushering in "" A good start." Zhao Shouming pointed out that the company closely follows the pace of the country, pays close attention to product quality and safety, and focuses on the theme of the development of the big health industry, and is committed to building a large product development platform. The company has nearly 200 drug production approvals and 18 dosage forms to select and cultivate suitable for large products. For products in the development direction, on the premise of ensuring quality and promoting production, we will go all out to do a good job in product listing, and do a good job in the secondary development of the company's existing products in a targeted manner, and expand new uses of old drugs. In terms of new drug research and development, the company is currently cooperating with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences to develop Huperzine A series products, which are expected to be launched globally in the future.

At the meeting, Chen An, deputy general manager of the company's technology center, discussed the problems encountered by the company in the current state-issued generic drug consistency evaluation policy with President Hao Haiping and his party. Dean Hao Haiping pointed out that the time limit for consistency evaluation is short, and the selection of varieties is difficult. In addition, Dean Hao Haiping introduced the relevant situation of the School of Pharmacy, China Pharmaceutical University in simple terms, and discussed how to rely on the corporate advantages of Wanbangde Pharmaceutical Group, combined with the rich human resources of the School of Pharmacy, China Pharmaceutical University, to increase the cooperation between industry, academia and research. Promote the industrialization of scientific and technological achievements and promote the technological innovation of the pharmaceutical industry to conduct in-depth discussions and reach consensus, which will lay a solid foundation for the future cooperation between Wanbangde Pharmaceutical Group and the School of Pharmacy, China Pharmaceutical University.

Hao Haiping, Dean of the School of Pharmacy, China Pharmaceutical University, and his delegation took a group photo with Zhao Shouming, Chairman of the Group, and Chen An, Deputy General Manager